KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Net Cash Flow (2016 - 2025)

Edwards Lifesciences (EW) has 17 years of Net Cash Flow data on record, last reported at $241.2 million in Q4 2025.

  • For Q4 2025, Net Cash Flow rose 135.7% year-over-year to $241.2 million; the TTM value through Dec 2025 reached -$74.5 million, down 103.98%, while the annual FY2025 figure was -$74.5 million, 103.98% down from the prior year.
  • Net Cash Flow reached $241.2 million in Q4 2025 per EW's latest filing, up from -$594.2 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $2.1 billion in Q3 2024 and bottomed at -$675.6 million in Q4 2024.
  • Average Net Cash Flow over 5 years is $84.8 million, with a median of $122.8 million recorded in 2021.
  • Peak YoY movement for Net Cash Flow: tumbled 460.89% in 2021, then soared 827.79% in 2023.
  • A 5-year view of Net Cash Flow shows it stood at -$654.3 million in 2021, then rose by 29.56% to -$460.9 million in 2022, then skyrocketed by 43.05% to -$262.5 million in 2023, then tumbled by 157.37% to -$675.6 million in 2024, then surged by 135.7% to $241.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were $241.2 million in Q4 2025, -$594.2 million in Q3 2025, and $170.8 million in Q2 2025.